<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00122746</url>
  </required_header>
  <id_info>
    <org_study_id>E33022</org_study_id>
    <nct_id>NCT00122746</nct_id>
  </id_info>
  <brief_title>Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients</brief_title>
  <official_title>Doctoral CRP on Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Atomic Energy Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Atomic Energy Agency</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers plan:

        -  To undertake clinical studies of radiotherapy with or without the administration of the
           chemotherapeutic agent cisplatin, known to be a radiosensitizer;

        -  To perform pre-clinical studies of the radiosensitivity of human fibroblasts and
           cervical cancer cell lines in culture, with or without the addition of various HIV
           proteins or protease inhibitors, in order to determine the extent of any cellular
           radiosensitizing properties of these molecules;

        -  To develop strategies for sensitizing tumour cells to radiation, specifically by
           down-regulating specific viral proteins that are known to be factors associated with
           resistance to radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical study addresses the question of whether radiotherapy plus weekly cisplatin offers an
      advantage over the same radiotherapy given alone in AIDS patients with cervix cancer.
      External beam radiotherapy is used with 50 Gy in 25 daily fractions (last interim analysis,
      October 2005) suggested lowering the total dose down to 46 Gy in 23 daily fractions).
      Brachytherapy component was specified as either 30 Gy of LDR in a single fraction or 3
      fractions of 8 Gy using HDR. Cisplatin was administered weekly at a dose of 30 mg/sqm.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2004</start_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3 year recurrence free survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grade 3 acute toxicity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pelvic control rates</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumour response at 3 months.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer specific survival rates.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rates.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late toxicities after the treatment.</measure>
    <time_frame>up to 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">322</enrollment>
  <condition>Cancer of the Cervix</condition>
  <arm_group>
    <arm_group_label>Radiotherapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EBRT pelvis 46 Gy, 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy plus Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EBRT pelvis 46 Gy, 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy alone</intervention_name>
    <description>EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A</description>
    <arm_group_label>Radiotherapy alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy with cisplatin</intervention_name>
    <description>EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT</description>
    <arm_group_label>Radiotherapy plus Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cancer of the cervix

          -  AIDS

        Exclusion Criteria:

          -  Unable to give informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo H. Zubizarreta, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>International Atomic Energy Agency</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eduardo H. Zubizarreta, M.D.</last_name>
    <phone>+43-1-2600</phone>
    <phone_ext>22401</phone_ext>
    <email>e.h.zubizarreta@iaea.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept. of Atomic Energy, Tata Memorial Centre</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reena Engineer, MD</last_name>
      <email>reena_engineer@rediffmail.com</email>
    </contact>
    <investigator>
      <last_name>Reena Engineer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johannesburg Hospital</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ocean Road Cancer Institute</name>
      <address>
        <city>Dar Es Salaam</city>
        <country>Tanzania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Twalib Ngoma, MD</last_name>
      <email>ngoma@uccmail.co.tz</email>
    </contact>
    <investigator>
      <last_name>Twalib Ngoma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiotherapy Centre</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Kigula, MD</last_name>
      <email>jbkigula@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Kigula, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiotherapy Centre</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
    <country>South Africa</country>
    <country>Tanzania</country>
    <country>Uganda</country>
    <country>Zimbabwe</country>
  </location_countries>
  <link>
    <url>http://www.iaea.org</url>
    <description>International Atomic Energy Agency. Research Contracts Administration</description>
  </link>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2005</study_first_submitted>
  <study_first_submitted_qc>July 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2005</study_first_posted>
  <last_update_submitted>October 12, 2011</last_update_submitted>
  <last_update_submitted_qc>October 12, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical Cancer</keyword>
  <keyword>AIDS</keyword>
  <keyword>External Beam Radiotherapy</keyword>
  <keyword>Brachytherapy</keyword>
  <keyword>Cisplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

